Flavagline derivatives

Patent metadata

Field	Value
Publication number	US-10047064-B2
Application number	US-201515323650-A
Country	US
Kind code	B2
Filing date	Jul 6, 2015
Priority date	Jul 4, 2014
Publication date	Aug 14, 2018
Grant date	Aug 14, 2018

Abstract

The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.

First claim

The invention claimed is:

1. A compound of the following formula (I):

in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof,
or a pharmaceutically acceptable salt and/or solvate thereof,
wherein:
the solvate is an ethanolate or hydrate,
represents a single bond or a double bond,
n represents an integer between 1 and 10,
R 1 represents CO 2 R 10 , CONH 2 , NR 11 R 12 , NR 13 COR 14 , NR 15 CONR 16 R 17 , NR 18 CSNR 19 R 20 , NR 21 SO 2 R 22 , NR 23 CO 2 R 24 or an optionally substituted heteroaryl,
R 2 represents OH, or
R 1 and R 2 together form, with the carbon atoms which bear them, an optionally substituted heterocycle, the optionally substituted heterocycle not being:

 carbon 1 designating the carbon atom bearing the group R 1 and carbon 2 designating the carbon atom bearing the group R 2 ,
R 3 represents H, OR 25 , CHOHCH 2 OH, CHO, N 3 , NR 26 R 27 , CO 2 R 28 , CONR 29 R 30 , NR 38 COR 39 , (O(CH 2 ) m O(CH 2 ) p ) r (CH 2 ) q R 31 , (NR 32 (CH 2 ) w NR 33 (CH 2 ) x ) y (CH 2 ) z R 34 , ONR 84 R 85 , optionally substituted aryl or optionally substituted heteroaryl,
R 4 is absent when represents a double bond and R 4 represents H or OH when represents a single bond,
R 10 to R 30 , R 32 , R 33 , R 38 and R 39 represent, independently of each other, H or a (C 1 -C 6 )alkyl, aryl, aryl-(C 1 -C 6 )alkyl or (C 1 -C 6 )alkyl-aryl group, said group being optionally substituted by one or more groups selected from (C 1 -C 6 )alkyl, OR 35 and NR 36 R 37 , or
R 11 and R 12 , or R 16 and R 17 , or R 19 and R 20 , or R 26 and R 27 , or R 29 and R 30 , together form, with the nitrogen atom which bears them, an optionally substituted nitrogen-containing heterocycle,
R 31 and R 34 represent, independently of each other, H, OR 35 , NR 36 R 37 or a (C 1 -C 6 )alkyl, aryl, aryl-(C 1 -C 6 )alkyl, ONR 86 R 87 or (C 1 -C 6 )alkyl-aryl group, said group being optionally substituted by one or more groups selected from (C 1 -C 6 )alkyl, OR 35 and NR 36 R 37 ,
R 35 to R 37 and R 84 to R 87 represent, independently of each other, H or a (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl group,
Ra represents a halogen atom, CN or a (C 1 -C 6 )alkoxy group,
Rb represents H or a (C 1 -C 6 )alkoxy group, or
Ra and Rb together form an —OCH 2 O— chain, and
m, p, r, q, w, x, y, and z represent, independently of each other, an integer between 1 and 4, provided that when R 1 represents CO 2 R 10 or CONH 2 , R 3 represents CHOHCH 2 OH, CHO, N 3 , NR 26 R 27 , CO 2 R 28 , CONR 29 R 30 , NR 38 COR 39 , (O(CH 2 ) m O(CH 2 ) p ) r (CH 2 ) q R 31 or (NR 32 (CH 2 ) w NR 33 (CH 2 ) x ) y (CH 2 ) z R 34 .

2. The compound according to claim 1 , wherein n is between 1 and 4.

3. The compound according to claim 1 , wherein:
represents a single bond,
R 1 represents CO 2 R 10 or CONH 2 ,
R 3 represents OR 25 , CHOHCH 2 OH, CHO, N 3 , NR 26 R 27 , CO 2 R 28 , CONR 29 R 30 , NR 38 COR 39 , (O(CH 2 ) m O(CH 2 ) p ) r (CH 2 ) q R 31 , (NR 32 (CH 2 ) w NR 33 (CH 2 ) x )hd y(CH 2 ) z R 34 , ONR 84 R 85 , optionally substituted aryl or optionally substituted heteroaryl,
R 4 represents H, and
R 10 represents H or a (C 1 -C 6 )alkyl group.

4. The compound according to claim 1 , wherein:
represents a single bond,
R 1 represents NR 11 R 12 , NR 13 COR 14 , NR 15 CONR 16 R 17 , NR 18 CSNR 19 R 20 or NR 21 SO 2 R 22 , and
R 4 represents H.

5. The compound according to claim 1 , wherein:
represents a single bond,
R 1 represents

R 4 represents H,
R 40 represents H or a (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl group,
R 41 to R 43 represent, independently of each other, H or a (C 1 -C 6 )alkyl, aryl, aryl-(C 1 -C 6 )alkyl, OR 44 , SR 45 or NR 46 R 47 group,
R 44 to R 47 represent, independently of each other, H or a (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl group, said group being optionally substituted by one or more groups selected from (C 1 -C 6 )alkyl, OR 48 , NR 49 R 50 and polyamines, or
R 46 and R 47 together form, with the nitrogen atom which bears them, a nitrogen-containing heterocycle optionally substituted by a (C 1 -C 6 )alkyl group, and
R 48 to R 50 represent, independently of each other, H or a (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 )alkyl group.

6. The compound according to claim 1 , wherein the moiety

represents:

with:
R 60 , R 61 , R 65 , R 67 , R 68 , R 72 and R 75 representing, independently of each other, H or a (C 1 -C 6 ) alkyl, aryl or aryl-(C 1 -C 6 )alkyl group,
R 69 and R 70 representing, independently of each other, H or a (C 1 -C 6 )alkyl, aryl or aryl-(C 1 -C 6 ) alkyl group, or together forming, with the nitrogen atom which bears them, a nitrogen-containing heterocycle optionally substituted by a (C 1 -C 6 )alkyl group,
R 62 , R 63 , R 64 , R 66 , R 71 , R 73 and R 74 representing, independently of each other, H or a (C 1 -C 6 ) alkyl, aryl, aryl-(C 1 -C 6 )alkyl, OR 76 , SR 77 or NR 78 R 79 group, and
R 76 to R 79 representing, independently of each other, H or a (C 1 -C 6 )alkyl, aryl, aryl-(C 1 -C 6 ) alkyl or CN group, or
R 78 and R 79 together forming, with the nitrogen atom which bears them, a nitrogen-containing heterocycle optionally substituted by a (C 1 -C 6 )alkyl group.

7. The compound according to claim 1 , wherein, when represents a single bond, R 1 and R 2 are located on the same side of the cyclopentane ring to which they are linked.

8. The compound according to claim 1 , selected from the following compounds, in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof:

and the pharmaceutically acceptable salts and/or solvates thereof.

9. A pharmaceutical composition comprising at least one compound according to claim 1 and at least one pharmaceutically acceptable excipient.

10. The compound according to claim 1 , wherein:
R 1 is selected from optionally substituted triazoles and oxadiazoles, or
R 1 and R 2 together form, with the carbon atoms which bear them, an optionally substituted heterocycle selected from optionally substituted pyrimidine, pyrazole, pyrazolone, oxazoline, isoxazoline, oxazalanone, oxazalanethione, morpholinone and oxazepane rings, the optionally substituted heterocycle not being:

Assignees

• Pf Medicament

Inventors

• Marion Frédéric
• Kaloun El Bachir
• Lieby-Muller Frédéric
• Perez Michel
• Annereau Jean-Philippe
• Creancier Laurent

Classifications

• C07D405/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D491/048

  the oxygen-containing ring being five-membered · CPC title

• C07D307/93 Primary

  condensed with a ring other than six-membered · CPC title

• C07D498/04

  Ortho-condensed systems · CPC title